Zoetis (ZTS) to Announce Earnings on Thursday

Zoetis (NYSE:ZTS) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Zoetis to announce earnings of $1.85 per share and revenue of $2.5015 billion for the quarter. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.48 earnings per share. On average, analysts expect Zoetis to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Zoetis Trading Up 0.5%

Shares of NYSE:ZTS opened at $77.89 on Thursday. The company has a 50 day moving average of $77.21 and a 200-day moving average of $103.02. The firm has a market cap of $32.66 billion, a P/E ratio of 12.92, a P/E/G ratio of 1.21 and a beta of 0.75. Zoetis has a twelve month low of $71.47 and a twelve month high of $160.48. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.7%. Zoetis’s payout ratio is presently 35.16%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ZTS. Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Morgan Stanley lowered their price objective on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 22nd. TD Cowen decreased their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Citigroup reduced their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $118.33.

Insider Buying and Selling

In other news, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. lifted its position in shares of Zoetis by 3,311.3% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 158,250 shares of the company’s stock worth $19,912,000 after purchasing an additional 153,611 shares in the last quarter. Strive Financial Group LLC purchased a new position in Zoetis during the fourth quarter valued at approximately $390,000. Beacon Pointe Advisors LLC grew its position in Zoetis by 3.6% during the fourth quarter. Beacon Pointe Advisors LLC now owns 9,525 shares of the company’s stock valued at $1,198,000 after purchasing an additional 327 shares in the last quarter. First Citizens Bank & Trust Co. increased its stake in Zoetis by 34.8% in the 4th quarter. First Citizens Bank & Trust Co. now owns 58,495 shares of the company’s stock valued at $7,360,000 after buying an additional 15,115 shares during the period. Finally, EP Wealth Advisors LLC acquired a new position in Zoetis in the 4th quarter valued at approximately $35,365,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.